Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05172258
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:57.754449+00:00
Published At
2026-04-13T00:00:00+00:00
Record Updated At
2026-04-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Head and Neck Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT05172258"
protocolSection.identificationModule.officialTitle
"A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Hypopharyngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Laryngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Oral Cavity Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Oropharyngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Hypopharyngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Laryngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Oral Cavity Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Oropharyngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IV Hypopharyngeal Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Laryngeal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Lip and Oral Cavity Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.